Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP4 | P49662 | 1/20 | 0.36 |
| ▸ | CASP5 | P51878 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.31 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.31 |
| ▸ | MELK | Q14680 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30299383 | 0.82 | HRH3 (0.37) | — | |
| SCHEMBL30299398 | 0.77 | OPRM1 (0.34) | CASP1CASP4CASP5SIRT2SIRT1 | |
| SCHEMBL30299346 | 0.76 | RET (0.36) | CASP1CASP4CASP5CHRM4TRPC5 | |
| SCHEMBL30299387 | 0.74 | OPRM1 (0.31) | CASP1CASP4CASP5 | |
| SCHEMBL15759139 | 0.72 | CHRM5 (0.46) | CASP1CASP4CASP5SIRT2SIRT1 | |
| SCHEMBL30299364 | 0.70 | TLR9 (0.36) | — | |
| SCHEMBL10264854 | 0.70 | CASP1 (0.44) | CASP1CASP4CASP5SIRT2SIRT1 | |
| SCHEMBL10203176 | 0.69 | CASP1 (0.43) | CASP1CASP4CASP5SIRT2SIRT1 | |
| SCHEMBL467901 | 0.68 | CASP1 (0.43) | CASP1CASP4CASP5SIRT2SIRT1 | |
| SCHEMBL30299279 | 0.68 | LTA4H (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116075303-A | Method of selecting patients treated with a combination of an AXL inhibitor and an immune checkpoint modulator | 卑尔根生物股份公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115916344-A | AXL inhibitors for antiviral therapy | 卑尔根生物股份公司 | 2023-04-04 | — | — | CN | disclosed |